A61P 17 - Drugs for dermatological disorders

Patents for A61P 17 - Drugs for dermatological disorders (106,455)
12/2002
12/27/2002	WO2002055087B1 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain
12/27/2002	WO2002049593A3 Use of dna repair enzymes as mmp-1 inhibitors
12/27/2002	WO2002018445A8 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
12/27/2002	WO2002000877A3 Antisense oligonucleotides to inhibit angiogenesis and/or metastasis
12/27/2002	WO2001091856A3 Use of cox2 inhibitors for treating skin injury from exposure to ultraviolet radiation
12/27/2002	WO2001087935A9 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg)
12/27/2002	WO2001074903A9 Cd20/ige-receptor like molecules and uses thereof
12/27/2002	CA2455387A1 Fce fusion proteins for treatment of allergy and asthma
12/27/2002	CA2451874A1 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells
12/27/2002	CA2450936A1 Purine inhibitors of phosphodiesterase (pde) 7
12/27/2002	CA2450934A1 Pyrimidine inhibitors of phosphodiesterase (pde) 7
12/27/2002	CA2450809A1 Methods for detecting and treating the early onset of aging-related conditions
12/27/2002	CA2450793A1 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
12/27/2002	CA2450724A1 Quinazoline and pyrido¬2,3-d\|pyrimidine inhibitors of phosphodiesterase (pde) 7
12/27/2002	CA2450659A1 Tryptase inhibitors
12/27/2002	CA2450067A1 Proteins associated with cell growth, differentiation, and death
12/27/2002	CA2449910A1 Use of glycoprotein for the treatment and re-epithelialisation of wounds
12/27/2002	CA2449898A1 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
12/27/2002	CA2446285A1 Fibroblast growth factor and nucleic acid encoding same
12/27/2002	CA2435151A1 Method for treating psoriasis
12/27/2002	CA2430627A1 Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same
12/26/2002	US20020198266 Skin remedy, which allows gas transportation therethrough
12/26/2002	US20020198248 Therapeutic methods and compositions involving isoflavones
12/26/2002	US20020198236 Small organic molecule regulators of cell proliferation
12/26/2002	US20020198214 Such as (3-(4-(4-fluoro-benzyl)-piperidine-1-carbonyl)-4-methoxy-phenyl)-oxo-acetic acid methyl ester for proinflammation response in multiple sclerosis, inflammatory bowel disease, osteoarthritis, and other arthritic conditions
12/26/2002	US20020198192 A therapeutic formulation comprising a topically acceptable non-solid vehicle and carbamazepine for treating psoriasis skin disorder; gels, creams, ointments, lotions, liquids, and suspensions
12/26/2002	US20020198177 Coenzyme Q and EPA
12/26/2002	US20020198154 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor
12/26/2002	US20020198143 B7-like polynucleotides, polypeptides, and antibodies
12/26/2002	US20020197666 Human chordin-related proteins and polynucleotides encoding them
12/26/2002	US20020197633 Nucleotide sequence for use in the detection and analysis of gene expression associated with age resistance
12/26/2002	US20020197337 Hypericum Perforatum L. Oleoresin, Procedure for Obtaining it and Uses of it
12/26/2002	US20020197336 Wound healing antiscarring topical composition of centella and ginseng
12/26/2002	US20020197291 Mixture of urea, hydrophilic film forming compound and water
12/26/2002	US20020197288 Topical applying; mixture of fibers and ubiquinone
12/26/2002	US20020197286 Method for preventing and treating skin aging
12/26/2002	US20020197283 Chemical method of making a suspension, emulsion or dispersion of pyrithione particles
12/26/2002	US20020197233 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
12/26/2002	US20020197216 Cross-regulin composition of turmeric-derived tetrahydrocurcuminoids for skin lightening and protection against UVB rays
12/26/2002	CA2391588A1 Cosmetic or dermatological composition including an association between an elastase-inhibiting compound of the n-acylamino amides family and at least one anti-inflammatory compound
12/26/2002	CA2391585A1 Cosmetic or dermatological composition including an association between a compound of the n-acylamino amides family and at least one matrix metalloproteinase inhibitor
12/26/2002	CA2391580A1 Cosmetic or dermatological composition including an association between an elastase-inhibiting compound of the n-acylamino amides family and at least one antifungal agent or at least one antibacterial agent
12/26/2002	CA2391574A1 Cosmetic or dermatological composition including an association between an elastase-inhibiting compound of the n-acylamino amides family and at least one muscle relaxant agent
12/25/2002	CN1387576A Sequence-specific DNA recombination in ekaryotic cells
12/25/2002	CN1387531A Pyrazolo [4,3-d] pyrimidine derivs.
12/25/2002	CN1387530A Imidazopyridine derivs. used as phosphodiesterase VII inhibitors
12/25/2002	CN1387528A Heterocyclic substd, pyrazolones
12/25/2002	CN1387527A Qinazoline derivs. as VEGF inhibitors
12/25/2002	CN1387526A Cyclopropanes as CGRP antagonists, medicaments contg. said compounds and method for production thereof
12/25/2002	CN1387514A Aromatic sulfone hydroxamic acid metalloprotease inhibitor
12/25/2002	CN1387419A Microdermabrasion device
12/25/2002	CN1386547A High-solidifiability fibrinogen gelatin
12/25/2002	CN1386536A Medicine for treating dermatopathy
12/25/2002	CN1386530A Medicine for treating burn, sore and ulcer and its preparing process
12/25/2002	CN1386528A Disinfecting safflower tincture and its preparing process
12/25/2002	CN1386525A Formulation for face-beautifying product
12/25/2002	CN1386513A Ointment for treating burn and scald and its preparing process
12/25/2002	CN1386512A Liquid medicine for treating burns
12/25/2002	CN1386506A Sulfamine ointment
12/25/2002	CN1386493A Cosmetics or medical preparation contg. alkenylaminotriazine as sunlight ageing-proof agent, and alkenylaminotriazine
12/25/2002	CN1096861C Method of treating androgenic alopecia with 5-alpha reductase inhibitors
12/25/2002	CN1096856C Method for topical treatment of scar tissue and related tissue reaction to trauma
12/25/2002	CN1096843C Cosmatic and/or dermal composition contg. salicyclic acid
12/24/2002	US6498274 Amide derivatives for the treatment of diseases mediated by cytokines
12/24/2002	US6498171 Hydroxyomeprazole compositions
12/24/2002	US6498165 Pyrimidine compounds; prophylaxis and treatment of such as immune diseases, hyperproliferative disorders, cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis, psoriasis
12/24/2002	US6498162 Treating inflammatory and allergic diseases of respiratory tract and diseases of central nervous system
12/24/2002	US6497887 Delivery system for topical application to skin comprising freeze-dried, partially crosslinked polymeric gel membrane containing hyaluronic acid as disrupting agent, which can be returned to dissolvable gel upon application of wetting agent
12/24/2002	US6497866 Mixture containing anionic surfactants and nonionic emulsifiers
12/24/2002	CA2150812C Catechol diethers as selective pde iv inhibitors
12/23/2002	WO2001098255A1 Process for the production of calcium pantothenate
12/23/2002	CA2413413A1 Method for preparing calcium pantothenate
12/19/2002	WO2002101048A2 NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-7 GENE
12/19/2002	WO2002100899A2 Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
12/19/2002	WO2002100859A1 Pde iv inhibitors
12/19/2002	WO2002100849A2 Novel nitriles useful as reversible inhibitors of cysteine proteases
12/19/2002	WO2002100836A2 Compounds, compositions and methods for modulating beta-amyloid production
12/19/2002	WO2002100826A2 Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
12/19/2002	WO2002100819A1 N-arylphenylacetamide derivatives and medicinal compositions containing the same
12/19/2002	WO2002100445A1 Treatment and composition for wound healing
12/19/2002	WO2002100420A2 Pharmaceutical zeolite-based compositions containing zinc and erythromycin, to be used in the treatment of acne
12/19/2002	WO2002100405A1 Isoquinoline inhibitors of p38
12/19/2002	WO2002100383A1 Porous sponge-like cellulosic material for treatment of injuries
12/19/2002	WO2002100373A1 Skin preparation
12/19/2002	WO2002100359A1 Preparation for hair and/or scalp
12/19/2002	WO2002100354A2 Pyrrolo[2,3-d]pyrimidine nucleoside analogs
12/19/2002	WO2002100351A2 A method for treating inflammatory diseases by administering a ppar-delta agonist
12/19/2002	WO2002100341A2 Compounds for the treatment of metabolic disorders
12/19/2002	WO2002100332A2 Isoxazoline compounds having mif antagonist activity
12/19/2002	WO2002100330A2 METHODS OF ADMINISTERING ANTI-TNFα ANTIBODIES
12/19/2002	WO2002100327A2 Substituted 1-benzazepines and derivatives thereof
12/19/2002	WO2002100250A2 Wit 3.0, a novel gene to control soft tissue wound healing
12/19/2002	WO2002087583A3 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
12/19/2002	WO2002085906A3 Phthalazinones derivatives useful as pde4/7 inhibitors
12/19/2002	WO2002080754A3 Methods for using annexin for detecting cell death in vivo and treating associated conditions
12/19/2002	WO2002076405A3 Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
12/19/2002	WO2002074236A3 Skin whiteners containing hydroxytetronic acid
12/19/2002	WO2002070561A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002070560A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002070558A3 Nuclear hormone receptor ligand binding domain

1 ... 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 ... 1065